Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Treatment of Porphyromonas gulae infection and downstream pathology in the aged dog by lysine-gingipain inhibitor COR388.

Arastu-Kapur S, Nguyen M, Raha D, Ermini F, Haditsch U, Araujo J, De Lannoy IAM, Ryder MI, Dominy SS, Lynch C, Holsinger LJ.

Pharmacol Res Perspect. 2020 Feb;8(1):e00562. doi: 10.1002/prp2.562.


Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors.

Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, Nguyen M, Haditsch U, Raha D, Griffin C, Holsinger LJ, Arastu-Kapur S, Kaba S, Lee A, Ryder MI, Potempa B, Mydel P, Hellvard A, Adamowicz K, Hasturk H, Walker GD, Reynolds EC, Faull RLM, Curtis MA, Dragunow M, Potempa J.

Sci Adv. 2019 Jan 23;5(1):eaau3333. doi: 10.1126/sciadv.aau3333. eCollection 2019 Jan.


Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S.

Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, Brogi E, Brastianos PK, Hahn WC, Holsinger LJ, Massagué J, Leslie CS, Joyce JA.

Nat Cell Biol. 2014 Sep;16(9):876-88. doi: 10.1038/ncb3011. Epub 2014 Aug 3.


Extracellular domain dependence of PTPalpha transforming activity.

Tremper-Wells B, Resnick RJ, Zheng X, Holsinger LJ, Shalloway D.

Genes Cells. 2010 Jun;15(7):711-724. doi: 10.1111/j.1365-2443.2010.01410.x. Epub 2010 Jun 7.


Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model.

Elie BT, Gocheva V, Shree T, Dalrymple SA, Holsinger LJ, Joyce JA.

Biochimie. 2010 Nov;92(11):1618-24. doi: 10.1016/j.biochi.2010.04.023. Epub 2010 May 4.


The minimal essential core of a cysteine-based protein-tyrosine phosphatase revealed by a novel 16-kDa VH1-like phosphatase, VHZ.

Alonso A, Burkhalter S, Sasin J, Tautz L, Bogetz J, Huynh H, Bremer MC, Holsinger LJ, Godzik A, Mustelin T.

J Biol Chem. 2004 Aug 20;279(34):35768-74. Epub 2004 Jun 16.


VHY, a novel myristoylated testis-restricted dual specificity protein phosphatase related to VHX.

Alonso A, Narisawa S, Bogetz J, Tautz L, Hadzic R, Huynh H, Williams S, Gjörloff-Wingren A, Bremer MC, Holsinger LJ, Millan JL, Mustelin T.

J Biol Chem. 2004 Jul 30;279(31):32586-91. Epub 2004 May 11.


The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn).

Holsinger LJ, Ward K, Duffield B, Zachwieja J, Jallal B.

Oncogene. 2002 Oct 10;21(46):7067-76.


Defects in actin-cap formation in Vav-deficient mice implicate an actin requirement for lymphocyte signal transduction.

Holsinger LJ, Graef IA, Swat W, Chi T, Bautista DM, Davidson L, Lewis RS, Alt FW, Crabtree GR.

Curr Biol. 1998 May 7;8(10):563-72.


Proximity and orientation underlie signaling by the non-receptor tyrosine kinase ZAP70.

Graef IA, Holsinger LJ, Diver S, Schreiber SL, Crabtree GR.

EMBO J. 1997 Sep 15;16(18):5618-28.


Signal transduction in T lymphocytes using a conditional allele of Sos.

Holsinger LJ, Spencer DM, Austin DJ, Schreiber SL, Crabtree GR.

Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9810-4.


Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly.

Hughey PG, Roberts PC, Holsinger LJ, Zebedee SL, Lamb RA, Compans RW.

Virology. 1995 Oct 1;212(2):411-21.


Analysis of the posttranslational modifications of the influenza virus M2 protein.

Holsinger LJ, Shaughnessy MA, Micko A, Pinto LH, Lamb RA.

J Virol. 1995 Feb;69(2):1219-25.


Reconstitution of the influenza virus M2 ion channel in lipid bilayers.

Tosteson MT, Pinto LH, Holsinger LJ, Lamb RA.

J Membr Biol. 1994 Oct;142(1):117-26.


Influenza A virus M2 ion channel protein: a structure-function analysis.

Holsinger LJ, Nichani D, Pinto LH, Lamb RA.

J Virol. 1994 Mar;68(3):1551-63.


Influenza virus M2 protein has ion channel activity.

Pinto LH, Holsinger LJ, Lamb RA.

Cell. 1992 May 1;69(3):517-28.


Supplemental Content

Loading ...
Support Center